Page last updated: 2024-08-18

pyrroles and Leukemia, Prolymphocytic, T-Cell

pyrroles has been researched along with Leukemia, Prolymphocytic, T-Cell in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gomez-Arteaga, A; Horwitz, S; Inghirami, G; Margolskee, E; van Besien, K; Wei, MT	1

Other Studies

1 other study(ies) available for pyrroles and Leukemia, Prolymphocytic, T-Cell

Article	Year
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leukemia & lymphoma, 2019, Volume: 60, Issue:7 Topics: Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Mutation; Nitriles; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles	2019

Article

Year

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Leukemia & lymphoma, 2019, Volume: 60, Issue:7

Topics: Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Mutation; Nitriles; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles

2019